NovoCure Limited
NASDAQ:NVCR
20.62 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 605.22 | 509.338 | 537.84 | 535.031 | 494.366 | 351.318 | 248.069 | 177.026 | 82.888 | 33.087 | 15.49 | 10.359 |
| Cost of Revenue
| 137.181 | 128.28 | 114.867 | 114.877 | 106.501 | 88.606 | 80.048 | 55.609 | 46.282 | 20.61 | 10.036 | 7.013 |
| Gross Profit
| 468.039 | 381.058 | 422.973 | 420.154 | 387.865 | 262.712 | 168.021 | 121.417 | 36.606 | 12.477 | 5.454 | 3.346 |
| Gross Profit Ratio
| 0.773 | 0.748 | 0.786 | 0.785 | 0.785 | 0.748 | 0.677 | 0.686 | 0.442 | 0.377 | 0.352 | 0.323 |
| Reseach & Development Expenses
| 209.645 | 223.062 | 206.085 | 201.303 | 132.01 | 79.003 | 50.574 | 38.103 | 41.467 | 43.748 | 40.381 | 34.797 |
| General & Administrative Expenses
| 189.827 | 164.057 | 132.753 | 126.127 | 107.437 | 87.948 | 73.456 | 59.114 | 51.007 | 33.864 | 24.052 | 16.602 |
| Selling & Marketing Expenses
| 239.063 | 226.809 | 173.658 | 137.057 | 118.017 | 96.675 | 77.663 | 63.528 | 59.449 | 38.861 | 21.177 | 16.406 |
| SG&A
| 428.89 | 390.866 | 306.411 | 263.184 | 225.454 | 184.623 | 151.119 | 122.642 | 110.456 | 72.725 | 45.229 | 33.008 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 638.535 | 614.673 | 512.496 | 464.487 | 357.464 | 263.626 | 201.693 | 160.745 | 151.923 | 116.473 | 85.61 | 67.805 |
| Operating Income
| -170.496 | -232.87 | -89.523 | -44.333 | 21.251 | -0.914 | -33.672 | -39.328 | -115.317 | -103.996 | -80.156 | -64.459 |
| Operating Income Ratio
| -0.282 | -0.457 | -0.166 | -0.083 | 0.043 | -0.003 | -0.136 | -0.222 | -1.391 | -3.143 | -5.175 | -6.223 |
| Total Other Income Expenses Net
| 39.334 | 41.13 | 7.677 | -7.742 | -12.299 | -7.91 | -12.27 | -9.169 | -6.147 | -3.151 | -0.144 | -12.558 |
| Income Before Tax
| -131.162 | -191.74 | -81.846 | -52.075 | 18.102 | -8.824 | -45.942 | -48.497 | -121.464 | -107.147 | -80.3 | -77.017 |
| Income Before Tax Ratio
| -0.217 | -0.376 | -0.152 | -0.097 | 0.037 | -0.025 | -0.185 | -0.274 | -1.465 | -3.238 | -5.184 | -7.435 |
| Income Tax Expense
| 37.465 | 15.303 | 10.688 | 6.276 | -1.706 | -1.594 | 17.617 | 13.165 | 10.381 | 4.434 | 0.382 | 0.353 |
| Net Income
| -168.627 | -207.043 | -92.534 | -58.351 | 19.808 | -7.23 | -63.559 | -61.662 | -131.845 | -111.581 | -80.682 | -77.37 |
| Net Income Ratio
| -0.279 | -0.406 | -0.172 | -0.109 | 0.04 | -0.021 | -0.256 | -0.348 | -1.591 | -3.372 | -5.209 | -7.469 |
| EPS
| -1.56 | -1.95 | -0.88 | -0.56 | 0.2 | -0.074 | -0.69 | -0.7 | -1.54 | -3.67 | -1.12 | -1.07 |
| EPS Diluted
| -1.56 | -1.95 | -0.88 | -0.56 | 0.18 | -0.074 | -0.69 | -0.7 | -1.54 | -3.67 | -1.12 | -1.07 |
| EBITDA
| -109.584 | -175.865 | -63.109 | -38.384 | 45.302 | 14.212 | -23.445 | -29.127 | -108.89 | -101.115 | -78.193 | -63.133 |
| EBITDA Ratio
| -0.181 | -0.345 | -0.166 | -0.083 | 0.061 | -0.003 | -0.136 | -0.222 | -1.391 | -3.143 | -5.048 | -6.611 |